ImaginAb Inc., a clinical stage immuno-oncology imaging company, congratulates Dr. Antoni Ribas, Ph.D., member of its Science Advisory Board, on his selection as President-Elect for The American Association for Cancer Research (AACR).
ImaginAb Inc., a clinical stage immuno-oncology imaging company, today announces its Founder and Chief Scientific Officer Dr. Anna Wu, Ph.D. is scheduled to present at this year’s American Association of Cancer Research Annual Meeting (AACR). Dr. Wu will speak on Tuesday, April 2, 2019, during the session on Molecular Imaging for Cancer Immunotherapy.
ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately. In addition, Tim Irish has joined ImaginAb’s Board of Directors as an independent non-executive Director and Jeffrey Evelhoch, Ph.D. has joined the Company’s Scientific Advisory Board.
ImaginAb Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8+ T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues.
ImaginAb Inc., an immuno-oncology imaging company, today announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics (Nasdaq: NKTR). Under the terms of the agreement, Nektar will use ImaginAb’s CD8 ImmunoPET technology to measure whole body and tumor CD8+ T cells’ density and distribution in cancer patients.